Liquid Biopsies in Hepatocellular Carcinoma: Clinical Perspectives

hepatocellular carcinoma (HCC) – accounting for 75-85%⁤ of primary liver cancers – is the 3rd leading cause of cancer death worldwide (2,⁣ 3).It occurs predominantly in patients with chronic liver disease (viral hepatitis B‍ and C, alcohol, metabolic steatosis), which complicates early‍ detection. ⁢Despite recommendations for semi-annual surveillance by ultrasound +/- alpha-fetoprotein (AFP) in cirrhotic patients, more than 60% of HCCs are still diagnosed at an intermediate or advanced stage, limiting access to curative ⁤treatments. AFP,a ancient serum biomarker,has moderate ⁤sensitivity⁢ (60-70%) and imperfect specificity for HCC diagnosis,particularly in ⁤cases of active liver inflammation.These limitations have ‍favored the emergence of liquid biopsy strategies, for a non-invasive and dynamic assessment of tumor biology. Liquid biopsies are⁢ thus based⁣ on the analysis of several circulating analytes, reflecting different aspects of HCC.

Protein biomarkers

to begin with, protein biomarkers remain the most accessible in clinical practice. AFP ⁢retains prognostic value, but its isolated diagnostic interest is‍ limited.AFP-L3%,a glycosylated isoform specific to tumor cells,and des-gamma-carboxy-prothrombin (DCP) have shown self-reliant value. Thier combination⁤ within the galad score (sex, ⁣age, AFP, AFP-L3, DCP) considerably⁢ improves HCC detection, with areas⁢ under the‍ curve (AUC) reported between 0.78 and 0.94, including‍ for small tumors and AFP-negative patients (1).

Genetic signals

Other elements of interest, circulating free DNA (cfDNA) and its tumor fraction‍ (ctDNA) provide more specific details about the ⁣tumor. Beyond somatic mutations, ‍DNA methylation alterations constitute an early signal of liver carcinogenesis. Several models based on differentially methylated regions have achieved high diagnostic performance, with sensitivities ⁣close to ⁢90%, specificities greater than 90% and AUCs up to 0.99, including for stage⁤ I HCCs (1). these signatures outperform AFP and maintain⁣ their‍ performance in⁤ AFP-negative forms. In addition, certain methylation signatures are associated with ⁣the risk of recurrence after curative treatment, suggesting a potential role in the detection of minimal residual disease.

Okay, I understand the constraints. I will perform an adversarial research check on the provided text, focusing on verifying claims and seeking contradictory information. I will not rewrite, paraphrase, or reuse any part of⁢ the provided text. My goal is to assess ⁣the reliability of the information presented.

Here’s my plan, broken down by⁣ claim, with⁣ a focus on ⁤recent (2024-2025) information where possible:

I. General Context & Statistics (Implied – GLOBOCAN 2022)

* Claim: The text implicitly relies on⁣ the global statistics of Hepatocellular Carcinoma (HCC) incidence and mortality.
* Verification: The text cites Bray et al. (2024) GLOBOCAN estimates. GLOBOCAN 2022 is a standard source for these statistics. I will confirm key⁤ figures (incidence, mortality) from GLOBOCAN 2022 via the IARC website (https://www.iarc.who.int/).
* ⁣ Adversarial Check: I will search for more recent (2024) HCC incidence/mortality⁢ updates from other reputable sources (e.g., American cancer Society, National Cancer Institute) to see if there are important discrepancies.

II. Alpha-Fetoprotein (AFP) as a Biomarker (Not explicitly stated, but implied as a⁢ baseline)

* Claim: AFP is a commonly‍ used, but imperfect, biomarker for HCC.
* Verification: This is widely accepted in the medical literature. ⁣I will confirm this via NCI and ACS resources.
* Adversarial Check: I will look for recent studies ‍questioning the utility of AFP, or highlighting its limitations even further than implied.

III. Circulating Tumor Cells (CTCs)

* Claim: CTCs are a direct marker of metastatic potential, associated with increased risk of recurrence ⁢and decreased survival. Sensitivity of ‍0.95 reported in a meta-analysis. Phenotypic/transcriptomic analysis of CTCs can aid treatment selection. Implementation ⁢is⁤ early-stage, mostly retrospective. CTC analysis provides complementary information to AFP.
* Verification: I will search PubMed (and Google Scholar) for meta-analyses on CTCs in HCC, specifically looking for studies reporting sensitivity around 0.95. I ‍will also look for studies on the prognostic value of ctcs.
* Adversarial Check: I will search for studies disputing the⁢ prognostic value of CTCs in HCC, or highlighting technical challenges in CTC detection that might explain variability in results. I will also look for studies showing⁢ no added benefit ⁢of CTC analysis beyond AFP.

IV. Exosomes and Circulating RNA⁤ (microRNA, long noncoding RNA)

* ‍ Claim: Exosomes carry ⁢microRNAs involved in angiogenesis, invasion, and resistance. miR-21,miR-221,miR-222 are overexpressed,miR-122 is ‍frequently⁤ enough decreased.Panels combining RNA and protein biomarkers have⁣ >90% sensitivity.
* Verification: I will search PubMed for studies on the role of these specific microRNAs (miR-21, miR-221, miR-222, miR-122) in HCC, and their association with prognosis. I will also look for studies ‍reporting sensitivity >90% for combined panels.
* Adversarial Check: I will search for studies questioning the specificity of these microRNAs for HCC (i.e.,are they also elevated in other cancers or liver diseases?),or highlighting ⁢challenges ‍in standardizing exosome/RNA isolation‍ and analysis. I will look for studies showing lower sensitivity for combined‍ panels.

V.Multi-Analytic Approaches

* Claim: Multi-analytic approaches (proteins, cfDNA methylation, CTCs) are the most performant, with AUC > 0.90, and coudl become standard⁣ for personalized surveillance.
* Verification: I will search PubMed⁢ for studies comparing the performance of single biomarkers vs.multi-analytic ⁢approaches in HCC detection/prognosis, focusing on AUC values.
* Adversarial Check: I will look for studies ⁢arguing that the cost and complexity of multi-analytic approaches outweigh their benefits, or that simpler biomarkers remain sufficient for most ⁣clinical scenarios.

Tools I will use:

* PubMed (https://pubmed.ncbi.nlm.nih.gov/)
* Google Scholar (https://scholar.google.com/)
* IARC GLOBOCAN ([https://www.iarc.who.int/](https://www.iarc.who.int